Hemihyperplasia, also called hemihypertrophy, is a rare condition where one side of the body grows more than the other. This difference in size can affect the arms, legs, face, or the entire half of the body. The main concern for parents and doctors is that children with this condition have a higher risk of developing certain childhood cancers, particularly Wilms tumor and hepatoblastoma.
What Causes Hemihyperplasia?
The exact cause of hemihyperplasia is not fully understood, but genetics play a central role. In many cases, the condition appears randomly with no family history. In other cases, it is linked to changes in genes that control how cells grow and divide.
Some children with hemihyperplasia have a condition called Beckwith-Wiedemann syndrome. This syndrome involves specific genetic changes on chromosome 11. These changes can cause overgrowth in specific parts of the body. Other genetic conditions, such as Russell-Silver syndrome, can also cause asymmetric growth, though the pattern of growth is different.
It is important to know that hemihyperplasia is not caused by anything a parent did or did not do. It is not related to diet, exercise, or lifestyle during pregnancy. The condition develops before birth as the embryo forms.
How Is Hemihyperplasia Diagnosed?
Doctors usually diagnose hemihyperplasia by physical examination. The key finding is a visible and measurable difference in size between the two sides of the body. This difference can be in length, width, or both. The arms and legs are the most common areas affected.
Measurements are taken at regular visits to track growth over time. Doctors may measure the length of the arms, legs, hands, and feet. They may also measure the circumference of the limbs. A difference of more than 2 centimeters between the two sides is often considered significant, though this number alone does not confirm the diagnosis.
Sometimes doctors order imaging tests like X-rays to check bone length. Genetic testing may be offered to look for known mutations. However, many children with hemihyperplasia have no identifiable genetic cause. In these cases, the diagnosis is based on the physical findings alone.
What Are the Risks of Hemihyperplasia?
The most serious risk associated with hemihyperplasia is the increased chance of developing certain childhood cancers. The two most common are Wilms tumor, a cancer of the kidney, and hepatoblastoma, a cancer of the liver. Research consistently shows that children with hemihyperplasia have a higher risk of these tumors compared to the general population.
The exact level of risk is debated because the condition is rare and studies vary. Some research suggests the risk may be around 5 to 10 percent, but this number is not precise across all studies. The risk is highest in the first few years of life. Most cases of Wilms tumor and hepatoblastoma in these children are diagnosed before age 7.
It is critical to understand that most children with hemihyperplasia do not develop cancer. The increased risk means extra monitoring is needed, not that cancer is expected. Regular screening is designed to catch any tumor early, when treatment is most effective.
How Often Should Children Be Screened?
Because of the cancer risk, doctors recommend regular screening for children with hemihyperplasia. The standard approach involves an ultrasound of the abdomen every 3 months until the child reaches a certain age. Most guidelines suggest continuing this screening until age 7, though some extend it to age 8.
The ultrasound checks the kidneys and liver for any abnormal growth. Blood tests for a protein called alpha-fetoprotein (AFP) may also be done. High levels of AFP can be a sign of hepatoblastoma. However, AFP levels are naturally high in infants, so doctors interpret these results carefully.
This screening protocol is widely accepted in pediatric oncology. It is not a guarantee that cancer will be prevented. The goal is early detection. When Wilms tumor or hepatoblastoma is found early, the survival rates are very high, often above 90 percent with proper treatment.
What Treatments Are Available for Hemihyperplasia?
Hemihyperplasia itself is not a disease that requires treatment in all cases. The focus is on managing the physical differences and monitoring for complications. Many children lead normal, healthy lives with no treatment beyond regular checkups.
For significant leg length differences, orthopedic treatment may be needed. A small difference can be managed with a shoe lift inside the shoe. This helps the child walk evenly and prevents back or hip problems. For larger differences, surgery may be an option. This can involve slowing the growth of the longer leg or lengthening the shorter leg. These procedures are typically done in specialized children’s hospitals.
In cases where one arm is longer, treatment is less common. Arm length differences rarely cause functional problems. Surgery is usually reserved for very large differences that interfere with daily activities.
Some families consider cosmetic surgery for facial asymmetry. This is a personal decision that should be made with a team of specialists, including a plastic surgeon, an orthopedic surgeon, and a genetic counselor. The evidence for the long-term benefits of cosmetic surgery in this context is limited.
What Is the Long-Term Outlook?
The long-term outlook for children with hemihyperplasia is generally good. The growth difference often becomes less noticeable as the child grows. In some cases, the difference stays stable. In others, it becomes more proportional over time.
The most important factor in the outlook is the cancer screening. Children who undergo regular screening until the recommended age have the best chance of early detection if a tumor develops. After age 7 or 8, the cancer risk drops significantly, and most children transition to normal pediatric care.
Adults with hemihyperplasia generally do not need special monitoring. The cancer risk associated with the condition is largely limited to childhood. However, adults may still notice a difference in limb size or shoe size. This is a normal part of the condition and does not usually cause health problems.
One non-obvious point: hemihyperplasia can affect internal organs, not just the limbs. The kidneys, liver, and spleen on the larger side may also be bigger. This is why the abdominal ultrasound is so important. The doctor is not just looking for tumors; they are also checking that the organs are developing normally.
When Should Parents Seek Genetic Counseling?
Genetic counseling is recommended for families of children with hemihyperplasia. A genetic counselor can explain the risks of the condition and discuss testing options. This is especially helpful when the family is considering having more children.
Most cases of isolated hemihyperplasia are not inherited. They occur randomly. However, some genetic syndromes associated with hemihyperplasia can be passed down. A genetic counselor can help determine the likelihood of this based on the child’s specific genetic findings.
Counseling also helps parents understand the screening schedule and why it is so important. It provides a clear roadmap for the first few years of the child’s life. This reduces anxiety and ensures that no screening appointments are missed.
Frequently Asked Questions
Is hemihyperplasia the same as hemihypertrophy?
Yes, the terms are used interchangeably. Hemihyperplasia is the more accurate medical term because the condition involves an increase in the number of cells, not just the size of the cells.
Can hemihyperplasia be cured?
There is no cure because the condition is present from birth. Treatment focuses on managing symptoms, monitoring for cancer risk, and addressing any functional issues like leg length differences.
Does hemihyperplasia affect intelligence?
No. Hemihyperplasia itself does not affect brain development or intelligence. If the condition is part of a genetic syndrome, other features of that syndrome may affect development, but isolated hemihyperplasia does not.
When does the cancer screening stop?
Screening typically continues until age 7 or 8. After this age, the risk of Wilms tumor and hepatoblastoma drops significantly, and routine screening is no longer recommended by most pediatric oncology guidelines.
